CAR-T Therapy | Santiago Thibaud, MD | ASH 2022

Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022
Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022
Effect of a Covid Infection in Patients Prior to Transplant | Meera Mohan, MD, MS, FACP | ASH 2022
Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022
Patient Top Concerns At and Since Diagnosis | Nathan Sweeney, PhD | ASH 2022
Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022
iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022
Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PhD | ASH 2022
Prospective Evaluation of the Biology of Aggressive Myeloma Lesions After Induction | ASH 2022
Detecting Myeloma with Single Cell Sequencing | Scott Goldsmith, MD | ASH 2022
What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022
(Guest Lecture): Relapsed Refractory Multiple Myeloma - Krina Patel, MD, MSc | RT Irvine, CA Nov 5, 2022